Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Caregiving can take many forms, often requiring a profound shift in daily life. While navigating a disease is an immense challenge for patients, managing the emotional, logistical and personal burdens ...

Rising awareness, innovative therapies, and evolving treatment options drive this growth.

With thousands of press releases published each week, it can be difficult to keep up with everything on. To help healthcare ...

Clinicians may one day be able to treat immune checkpoint inhibitor-related myocarditis without disrupting cancer therapy, findings from a cellular investigation showed.Individuals who die of immune ...

The generic drugmaker was the top loser on the Nifty Pharma index and the benchmark Nifty 50 index. "The drop in shares comes ...

This was the stock's third consecutive day of gains.

As many American companies beat a hasty retreat from the diversity, equity and inclusion programs they once embraced, the bulk retailer Costco Wholesale Corp. has become one of DEI’s few remaining ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

The two biggest questions for SCHD right now are 1) what’s caused it to underperform so badly, even within its category and 2) will those trends continue into 2025.

Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive ...